Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research B cell 

    • Chronic lymphocytic leukemia (CLL) 

    • Treating CLL 

    • Initiating treatment 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
      • Glycoengineering
      • Fundamental concepts in B-cell malignancies
      • Chronic lymphocytic leukemia (CLL)
        • Diagnosis and prognosis
        • Treating CLL
          • Initiating treatment
          • Individualizing treatment
          • The evolving CLL treatment landscape
          • Goals of treatment
        • Emerging therapeutic options
        • Current issues in CLL
        • References
      • Follicular non-Hodgkin's lymphoma (fNHL)
      • Diffuse large B-cell lymphoma (DLBCL)
      • Slide decks, videos and downloads
    • Research BRAF
    • Research Cancer Immunotherapy
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • CLL
    • DLBCL
    • Follicular Lymphoma
  • Biological Pathways
    • Apoptosis
    • B-cell Surface Proteins
  • Clinical Trials
    • CLL
  • Cancer Biomarkers
    • CLL
      • Anti-CD22 ADC (DCDT2980S)
      • CD22
      • CD79b
  • Future Directions
    • Non-Antibody Biologics
      • Apoptosis
    • Targeted Small Molecules
      • Apoptosis
    • Traditional Monoclonal Antibodies
      • B-cell Surface Proteins
Share

Initiating treatment

  • Factors such as significant disease-related symptoms, bulky disease, and lymphocyte and platelet counts are important in determining when to initiate treatment12
  • Disease stage and the presence of progressive disease also are important factors in deciding when to initiate therapy
    • For patients with asymptomatic early-stage disease (Rai stage I or II, Binet stage A or B), a watch-and-wait approach has been suggested11,12,27
    • Initiation of treatment is recommended for patients with symptomatic, advanced, or progressive disease,27 and intermediate- and high-risk disease9

View References for this site section

 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: Individualizing treatment »

© 2011 Genentech USA, Inc. All rights reserved